Document Detail

Treatments for Noncutaneous Melanoma.
MedLine Citation:
PMID:  24880944     Owner:  NLM     Status:  Publisher    
Historically the approach to treating noncutaneous melanoma was largely guided by the experience with cutaneous melanoma, particularly in the metastatic setting. However, as genetic tools have allowed clinicians to better characterize these malignancies, their unique biology has become apparent. The ability to accurately distinguish the subtypes of melanoma and the genetic alterations that drive them is beginning to yield the tools that are shifting this disease from one that has proved to be intractable in the advanced setting to one that can be effectively treated.
Danny N Khalil; Richard D Carvajal
Related Documents :
2367584 - Pilomatrical carcinoma.
24332614 - Torsion of fallopian tube remnant associated with noncommunicating rudimentary horn in ...
8593714 - Neuropeptides and general neuronal marker in psoriasis--an immunohistochemical study.
24963964 - The premature ejaculation diagnostic tool (pedt): linguistic validity of the chinese ve...
14199084 - Visible masses of the cranial vault and its coverings.
17607124 - Recurrent primary synovial sarcoma of the chest wall.
Publication Detail:
Type:  REVIEW    
Journal Detail:
Title:  Hematology/oncology clinics of North America     Volume:  28     ISSN:  1558-1977     ISO Abbreviation:  Hematol. Oncol. Clin. North Am.     Publication Date:  2014 Jun 
Date Detail:
Created Date:  2014-6-1     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8709473     Medline TA:  Hematol Oncol Clin North Am     Country:  -    
Other Details:
Languages:  ENG     Pagination:  507-521     Citation Subset:  -    
Copyright Information:
Copyright © 2014 Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Targeted Therapies for Cutaneous Melanoma.
Next Document:  Targeted Therapy Resistance Mechanisms and Therapeutic Implications in Melanoma.